實驗原理 :

（1）公司產品僅用于科研特異性結合抗原：抗體本身不能直接溶解或殺傷帶有特異抗原的靶細胞，通常需要補體或吞噬細胞等共同發揮效應以清除病原微生物或導致病理損傷。然而，抗體可通過與病毒或毒素的特異性結合，直接發揮中和病毒的作用。

（2）活補體：IgM、IgG1、IgG2和IgG3可通過經典途徑激活補體，凝聚的IgA、IgG4和IgE可通過替代途徑激活補體。

（3）結合細胞：不同類別的免疫球蛋白，可結合不同種的細胞，參與免疫應答。

（4）可通過胎盤及粘膜：免疫球蛋白G（IgG）能通過胎盤進入胎兒血流中，使胎兒形成自然被動免疫。免疫球蛋白A（IgA）可通過消化道及呼吸道粘膜，是粘膜局部抗感染免疫的主要因素。

（5）具有抗原性：抗體分子是一種蛋白質，也具有刺機體產生免疫應答的性能。不同的免疫球蛋白分子，各具有不同的抗原性。

（6）抗體對理化因子的抵抗力與一般球蛋白相同：不耐熱，60～70℃即被破壞。各種酶及能使蛋白質凝固變性的物質，均能破壞抗體的作用。抗體可被中性鹽類沉淀。在生產上常可用硫酸銨或*從免疫血清中沉淀出含有抗體的球蛋白，再經透析法將其純化。
商品詳情：
英文名稱：Phospho-RSK2 (Ser227)

別    名:RSK2 (Phospho Ser227); RSK2 (Phospho S227); Rsk 2; MAPKAP Kinase 1b; MAP kinase activated protein kinase 1b; MAPK activated protein kinase 1b; 90 kDa ribosomal protein S6 kinase 3; HU2; HU3; Insulin stimulated protein kinase 1; ISPK1; MAPKAPK 1b; MAPKAPK1B; MRX19; p90 RSK3; p90RSK3; pp90RSK2; Ribosomal protein S6 kinase 90kDa polypeptide 3; Ribosomal protein S6 kinase alpha 3; Ribosomal S6 kinase 2; RPS6KA3; S6 kinase 2; S6K alpha3; KS6A3_HUMAN; CLS; RSK; HU-3; RSK2; MRX19; ISPK-1; p90-RSK2; S6K-alpha3.

產品類型磷酸化抗體

研究領域:信號轉導  激酶和磷酸酶

抗體來源:Rabbit

克隆類型:Polyclonal

交叉反應:Human,  (predicted: Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, )

產品應用:ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復）

not yet tested in other applications.

optimal dilutions/concentrations should be determined by the end user.

理論分子量:84kDa

細胞定位:細胞核 細胞漿

性    狀:Liquid

濃    度:1mg/ml

免 疫 原:KLH conjugated Synthesised phosphopeptide derived from human RSK2 around the phosphorylation site of Ser227: AY(p-S)FC

亞    型:IgG

純化方法:affinity purified by Protein A

保存條件:Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

注意事項:This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

產品介紹:This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 non-identical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Mutations in this gene have been associated with Coffin-Lowry syndrome (CLS). [provided by RefSeq, Jul 2008]

Function:

Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3. Phosphorylates DAPK1.

商品屬性：

抗體的標記實驗要點：

1.如在反應混合液中有疊氮鈉或游離氨基存在,會抑制標記反應。因此,蛋白質在反應前要對 0.1mol/L緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待化蛋白質之間的分子比按蛋白質表面的ε-氨基的密度會有所不同,選擇不當則影響標記的效率,應先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結合位點可能因此被封閉,導致抗體失活；

4.由于抗體的氨基不易接近可能造成化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結合位點時,或位于酶的催化位點時,化會降低或損傷抗體蛋白的結合力或活性；

6.還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及基,也可與糖基共價結合；

7.交聯反應后,應充分透析,否則,殘余的會對化抗體與親和素的結合產生競爭作用；

8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導致高本底。
一抗和二抗的區別：

第一抗體就是平常所說的抗體，即能和抗原特異性結合。

第二抗體是能和抗體結合的，即抗體的抗體。主要用于檢測抗體的存在。

一抗是針對抗原的抗體，二抗是針對一抗的抗體。即抗體也可以充當抗原刺激機體產生抗體。也就是說，抗原進入機體刺激機體免疫系統產生免疫應答，由B細胞可以產生與相應抗原發生特異性結合的特殊蛋白質。

一抗二抗都是一種可以特異結合別的物質的基團，而且一抗可以至少結合兩種其他基團（底物和二抗）。

一抗：可以特異結合底物，就是識別出我們想要檢測的東西。一抗和底物結合與否用肉眼是看不出來的。

二抗：可以和一抗結合，并帶有可以被檢測出的標記(如帶熒光、放射性、化學發光或顯色基團），作用是檢測一抗。 如果一抗自己帶有可以被檢測出的標記(如帶熒光、放射性、化學發光或顯色基團），則不需要二抗。但這樣成本很高，因為一種一抗只識別一種底物。所以如今的設計一般是二抗帶上可檢測標記，再來檢測一抗。而一抗識別底物。這樣，當一抗結合到底物上，就可以通過二抗檢測出來。

公司正在出售的產品：